-DOCSTART- -X- O
Although -X- _ O
β-amyloid -X- _ O
( -X- _ O
Aβ -X- _ O
) -X- _ O
may -X- _ O
be -X- _ O
the -X- _ O
primary -X- _ O
driver -X- _ O
of -X- _ O
Alzheimer’s -X- _ O
disease -X- _ O
( -X- _ O
AD -X- _ O
) -X- _ O
pathology -X- _ O
, -X- _ O
accumulation -X- _ O
of -X- _ O
pathological -X- _ O
tau -X- _ O
correlates -X- _ O
with -X- _ O
dementia -X- _ O
in -X- _ O
AD -X- _ O
patients. -X- _ O
Thus -X- _ O
, -X- _ O
the -X- _ O
prevention -X- _ O
/ -X- _ O
inhibition -X- _ O
of -X- _ O
AD -X- _ O
may -X- _ O
require -X- _ O
vaccine -X- _ O
/ -X- _ O
s -X- _ O
targeting -X- _ O
Aβ -X- _ O
and -X- _ O
tau -X- _ O
simultaneously -X- _ O
or -X- _ O
sequentially. -X- _ O
Since -X- _ O
high -X- _ O
antibody -X- _ O
titers -X- _ O
are -X- _ O
required -X- _ O
for -X- _ O
AD -X- _ O
vaccine -X- _ O
efficacy -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
decided -X- _ O
to -X- _ O
generate -X- _ O
vaccines -X- _ B-Intervention
, -X- _ I-Intervention
targeting -X- _ I-Intervention
Aβ -X- _ I-Intervention
( -X- _ I-Intervention
AV-1959R -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
Tau -X- _ I-Intervention
( -X- _ I-Intervention
AV-1980R -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ I-Intervention
Aβ -X- _ I-Intervention
/ -X- _ I-Intervention
tau -X- _ I-Intervention
( -X- _ I-Intervention
AV-1953R -X- _ I-Intervention
) -X- _ I-Intervention
B -X- _ I-Intervention
cell -X- _ I-Intervention
epitopes -X- _ I-Intervention
, -X- _ O
based -X- _ O
on -X- _ O
immunogenic -X- _ O
MultiTEP -X- _ O
platform -X- _ O
and -X- _ O
evaluate -X- _ O
the -X- _ O
immunogenicity -X- _ O
of -X- _ O
these -X- _ O
vaccines -X- _ B-Comparison
formulated -X- _ I-Comparison
with -X- _ I-Comparison
Advax -X- _ I-Comparison
( -X- _ I-Comparison
CpG -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ I-Comparison
delta -X- _ I-Comparison
inulin -X- _ I-Comparison
, -X- _ I-Comparison
Alhydrogel -X- _ I-Comparison
( -X- _ I-Comparison
® -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ I-Comparison
Montanide-ISA51 -X- _ I-Comparison
, -X- _ I-Comparison
Montanide-ISA720 -X- _ I-Comparison
, -X- _ I-Comparison
MPLA-SM -X- _ I-Comparison
pharmaceutical -X- _ I-Comparison
grade -X- _ I-Comparison
adjuvants. -X- _ I-Comparison
Formulation -X- _ O
of -X- _ O
AV-1959R -X- _ O
in -X- _ O
Advax -X- _ O
( -X- _ O
CpG -X- _ O
) -X- _ O
induced -X- _ O
the -X- _ O
highest -X- _ O
cellular -X- _ O
and -X- _ O
humoral -X- _ O
immune -X- _ O
responses -X- _ O
in -X- _ O
mice. -X- _ B-Patient
The -X- _ O
dual-epitope -X- _ O
vaccine -X- _ O
, -X- _ O
AV-1953R -X- _ O
, -X- _ O
or -X- _ O
the -X- _ O
combination -X- _ O
of -X- _ O
AV-1959R -X- _ O
and -X- _ O
AV-1980R -X- _ O
vaccines -X- _ O
formulated -X- _ O
with -X- _ O
Advax -X- _ O
( -X- _ O
CpG -X- _ O
) -X- _ O
induced -X- _ O
robust -X- _ O
antibody -X- _ O
responses -X- _ O
against -X- _ O
various -X- _ O
forms -X- _ O
of -X- _ O
both -X- _ O
, -X- _ O
Aβ -X- _ O
and -X- _ O
tau -X- _ O
pathological -X- _ O
molecules. -X- _ O
While -X- _ O
anti-Aβ -X- _ O
antibody -X- _ O
titers -X- _ O
after -X- _ O
AV-1953R -X- _ O
immunization -X- _ O
were -X- _ O
similar -X- _ O
to -X- _ O
that -X- _ O
in -X- _ O
mice -X- _ B-Patient
vaccinated -X- _ O
with -X- _ O
AV-1959R -X- _ O
or -X- _ O
AV-1959R -X- _ O
/ -X- _ O
AV-1980R -X- _ O
combination -X- _ O
, -X- _ O
anti-tau -X- _ O
titers -X- _ O
were -X- _ O
significantly -X- _ O
lower -X- _ O
after -X- _ O
AV-1953R -X- _ O
injection -X- _ O
when -X- _ O
compared -X- _ O
to -X- _ O
the -X- _ O
AV-1980R -X- _ O
or -X- _ O
AV-1959R -X- _ O
/ -X- _ O
AV-1980R. -X- _ O
In -X- _ O
silico -X- _ O
3D-modeling -X- _ O
provided -X- _ O
insight -X- _ O
into -X- _ O
the -X- _ O
differences -X- _ O
in -X- _ O
immunogenicity -X- _ O
of -X- _ O
these -X- _ O
vaccine -X- _ O
constructs. -X- _ O
In -X- _ O
sum -X- _ O
, -X- _ O
AV-1959R -X- _ B-Outcome
and -X- _ I-Outcome
AV-1980R -X- _ I-Outcome
formulated -X- _ I-Outcome
with -X- _ I-Outcome
Advax -X- _ I-Outcome
( -X- _ I-Outcome
CpG -X- _ I-Outcome
) -X- _ I-Outcome
adjuvant -X- _ I-Outcome
were -X- _ I-Outcome
identified -X- _ I-Outcome
as -X- _ I-Outcome
promising -X- _ I-Outcome
immunogenic -X- _ I-Outcome
vaccines -X- _ I-Outcome
for -X- _ I-Outcome
ongoing -X- _ I-Outcome
pre-clinical -X- _ I-Outcome
assessment -X- _ I-Outcome
and -X- _ I-Outcome
future -X- _ I-Outcome
human -X- _ I-Outcome
clinical -X- _ I-Outcome
trials -X- _ I-Outcome
. -X- _ O

